文献速递精神分裂症与精神病性障碍

氯氮平为何独特有效于难治性精神分裂症:综述与假说

Why Is Clozapine Uniquely Effective in Treatment-Resistant Schizophrenia? A Review and Proposal.
PubMed 文献 · Biol Psychiatry · 2025-06-23

本文综述氯氮平在难治性精神分裂症(TRS)中独特疗效的潜在机制。谷氨酸和免疫假说未被证实与其他抗精神病药有差异;毒蕈碱受体(尤其M1和M4)作用及代谢物N-去甲氯氮平对M1的完全激动可能关键。较低D2受体占有率假说仍有争议;多受体作用可改善非精神病性症状。

要点

  • 氯氮平对毒蕈碱受体(M1、M4)的作用及N-去甲氯氮平对M1的完全激动可能是其独特疗效关键。
  • 谷氨酸异常和免疫 dysfunction 假说尚未证明与其他抗精神病药不同或与临床改善相关。
  • 较低D2受体占有率假说仍有争议;多受体作用可改善焦虑抑郁等非精神病性症状。

核心结论

  • 氯氮平在TRS中的独特疗效可能主要归因于其对毒蕈碱受体(尤其M1和M4)的作用及其代谢物N-去甲氯氮平对M1的完全激动。
  • 谷氨酸和免疫假说尚未被证实与其他抗精神病药有差异或与临床改善相关。
  • 较低D2受体占有率假说仍有争议;多受体作用可解释其对非精神病性症状的益处。

研究设计与样本

  • 本文为综述与假说提出,未报告系统检索范围或样本量。

主要发现

  • TRS患者显示谷氨酸异常,氯氮平对谷氨酸有广泛作用,但未证明与其他抗精神病药不同。
  • TRS中报告免疫功能障碍,氯氮平有抗炎作用,但未与临床改善相关。
  • 氯氮平对毒蕈碱受体(尤其M1和M4)有重要影响,其代谢物N-去甲氯氮平是M1的完全激动剂。
  • 氯氮平较低的D2受体占有率被假设可允许长期多巴胺阻断后出现的多巴胺受体超敏逐渐缓解,但该假说仍有争议。
  • 氯氮平与奥氮平、喹硫平共享某些受体特性,但其对毒蕈碱受体的亲和力可能是其在TRS中更有效的机制。

临床怎么用

  • 氯氮平的多受体作用可改善TRS中常见的非精神病性症状,如焦虑和抑郁。
  • 氯氮平对H1、5-HT1A和GABAB受体的结合可解释其抗焦虑作用,对5-HT1A、5-HT2A和5-HT7受体的作用可能解释其抗抑郁特性。

局限性

  • 谷氨酸和免疫假说尚未被证明与其他抗精神病药不同或与临床改善相关。
  • 较低D2受体占有率假说仍有争议。
  • 毒蕈碱机制假说仍需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A great deal is known about the use, benefits, and side effects of clozapine in treatment-resistant schizophrenia (TRS). However, why clozapine is more effective than other antipsychotics in TRS remains unclear. In this article, we address this question. Patients with TRS show glutamate abnormalities, and clozapine has widespread effects on glutamate. However, these actions have not been proven to be different from those of other antipsychotics. Immune dysfunction is also reported in TRS, and clozapine has anti-inflammatory actions, but these have not been correlated with clinical improvement. Currently, there is a great deal of interest in muscarinic abnormalities in psychosis. Unlike most antipsychotics, clozapine has important effects on muscarinic receptors, particularly M1 and M4, and its major metabolite, N-desmethylclozapine, is a full agonist at M1. These effects are likely crucial to clozapine's effectiveness. In addition, clozapine's lower dopamine D2 receptor occupancy has been postulated to allow gradual resolution of dopamine receptor supersensitivity in the minority of patients with TRS who initially respond to antipsychotics but become resistant following long-term dopamine blockade. However, this hypothesis remains controversial. Clozapine's multireceptor profile enables it to have beneficial actions on the nonpsychotic symptoms common in TRS; its ability to bind to histamine H1, serotonin 5-HT1A, and GABAB (gamma-aminobutyric acid B) receptors offers an explanation for its anxiolytic actions, while effects on 5-HT1A, 5-HT2A, and 5-HT7 receptors likely underlie its antidepressant properties. Clozapine shares these properties with olanzapine and quetiapine, but its affinity for muscarinic receptors may be the mechanism by which it is more effective in TRS.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Murray RM, Egerton A, Gao Y, et al. Why Is Clozapine Uniquely Effective in Treatment-Resistant Schizophrenia? A Review and Proposal. Biol Psychiatry. 2025. PMID: 40562225. doi:10.1016/j.biopsych.2025.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。